EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Still the one: Transcriptional control across leukopoiesis by SPI1/PU.1

Joseph Mackie, Sangwan Sim, Lauren Y. Cominsky, Peter A. Nigrovic, Neil Romberg

Journal of Human Immunity · 2027-01-04 · 3 (1)

DOI: 10.70962/jhi.20260152 ↗
AbstractBibliografische Angaben

Abstract

The transcription factor (TF) SPI1 (historically called PU.1) is a critical pioneer TF and regulator of hematopoiesis. It exerts exquisitely dose-dependent and stage-specific control over lymphoid, myeloid, and central nervous system–resident lineages. Structurally characterized by an intrinsically disordered N-terminal transactivation region and a highly conserved C-terminal DNA-binding E26 transformation–specific domain, SPI1 can operate alone as a monomer, via homodimerization, through epigenetic interactions, and in context-dependent transcriptional partnerships. While early animal models established its essentiality for leukopoiesis, modern human genomics has unveiled direct links between altered SPI1 function and disease. Heterozygous loss-of-function germline variants cause PU.1-mediated agammaglobulinemia, whereas somatic mutations and/or regulatory alterations can drive hematologic malignancies. Dysregulated SPI1 activity is also implicated in autoimmune diseases, including rheumatoid arthritis and systemic lupus erythematosus, and neurodegenerative disorders. This review reconciles foundational murine paradigms with emerging human translational data, highlights current therapeutic landscapes, and projects how single-cell multi-omics and advanced gene editing may shape future directions in the SPI1 biomedical field.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →